In a new 13D filing, Dennis Purcell‘s Aisling Capital reported lowering its stake in Agile Therapeutics Inc (NASDAQ:AGRX) to 2.28 million shares, which account for 7.9% of the company’s outstanding stock. The fund’s stake was reduced from 2.58 million shares held as of the end of June.
Agile Therapeutics Inc (NASDAQ:AGRX) is a pharmaceutical company that produces women’s health products, such as contraceptives. Over the past 12 months, the company’s stock has gained 1.39%. For the second quarter of 2016, Agile Therapeutics reported a loss per share of $0.29, and a net loss of $8.42 million, compared to a loss per share of $0.38 and a net loss of $8.49 million for the same quarter of the previous year.
Image Point Fr/Shutterstock.com
Eight investors in our database were bullish on Agile Therapeutics Inc (NASDAQ:AGRX) at the end of June, same as a quarter earlier. Some of the smart managers that reported long positions in the company as of June 30 included Phill Gross and Robert Atchinson’s Adage Capital Management, which held a position worth $12.94 million, Joseph Edelman’s Perceptive Advisors, with a position valued at $3.91 million, Chuck Royce’s Royce & Associates, James E. Flynn’s Deerfield Management, and Peter Kolchinsky’s RA Capital Management.
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
You can access the original SEC filing by clicking here.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Aisling Capital III | 2,275,455 | 0 | 2,275,455 | 0 | 2,275,455 | 7.9% |
| Aisling Capital Partners III | 2,275,455 | 0 | 2,275,455 | 0 | 2,275,455 | 7.9% |
| Aisling Capital Partners III | 2,275,455 | 0 | 2,275,455 | 0 | 2,275,455 | 7.9% |
| Steven Elms | 961 | 2,275,455 | 961 | 2,275,455 | 2,276,416 | 7.9% |
| Dennis Purcell | 1,879 | 2,275,455 | 1,879 | 2,275,455 | 2,277,334 | 7.9% |
| Andrew Schiff | 460 | 2,275,455 | 460 | 2,275,455 | 2,275,915 | 7.9% |
Follow Dennis Purcell's Aisling Capital
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 9 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 3)*
Agile Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
00847L100
(CUSIP Number)
Lloyd Appel
Aisling Capital
888 Seventh Avenue, 12th Floor
New York, NY 10106
(212) 651-6380
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 30, 2016
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Page 2 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 2 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital III, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 2,275,455 |
| 8 | SHARED VOTING POWER 0 | |
| 9 | SOLE DISPOSITIVE POWER 2,275,455 | |
| 10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,275,455 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.9% (See Item 5) | |
| 14 | TYPE OF REPORTING PERSON PN |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 3 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital Partners III, LP | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 2,275,455 |
| 8 | SHARED VOTING POWER 0 | |
| 9 | SOLE DISPOSITIVE POWER 2,275,455 | |
| 10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,275,455 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.9% (See Item 5) | |
| 14 | TYPE OF REPORTING PERSON PN |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 4 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Aisling Capital Partners III LLC | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 2,275,455 |
| 8 | SHARED VOTING POWER 0 | |
| 9 | SOLE DISPOSITIVE POWER 2,275,455 | |
| 10 | SHARED DISPOSITIVE POWER 0 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,275,455 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.9% (See Item 5) | |
| 14 | TYPE OF REPORTING PERSON OO |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 5 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Steven Elms | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 961 |
| 8 | SHARED VOTING POWER 2,275,455 | |
| 9 | SOLE DISPOSITIVE POWER 961 | |
| 10 | SHARED DISPOSITIVE POWER 2,275,455 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,276,416 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.9% (See Item 5) | |
| 14 | TYPE OF REPORTING PERSON IN |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 7 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Andrew Schiff | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) o (b) x |
| 3 | SEC USE ONLY | |
| 4 | SOURCE OF FUNDS OO | |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) | o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 460 |
| 8 | SHARED VOTING POWER 2,275,455 | |
| 9 | SOLE DISPOSITIVE POWER 460 | |
| 10 | SHARED DISPOSITIVE POWER 2,275,455 |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,275,915 | |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.9% (See Item 5) | |
| 14 | TYPE OF REPORTING PERSON IN |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 9 of 11 |
| Item 5. | Interest in Securities of the Issuer. |
Item 5 is amended and restated in its entirety as follows:
(a),(b)
| Reporting Person | Sole Voting and Dispositive Power | Shared Voting and Dispositive Power | Total Shares | % Ownership |
| Aisling Capital III, LP | 2,275,455 | 0 | 2,275,455 | 7.9 |
| Aisling Capital Partners III, LP | 2,275,455 | 0 | 2,275,455 | 7.9 |
| Aisling Capital Partners III LLC | 2,275,455 | 0 | 2,275,455 | 7.9 |
| Steve Elms | 961 | 2,275,455 | 2,276,416 | 7.9 |
| Dennis Purcell | 1,879 | 2,275,455 | 2,277,334 | 7.9 |
| Andrew Schiff | 460 | 2,275,455 | 2,275,915 | 7.9 |
The aggregate percentage of shares of Common Stock reported as owned by each Reporting Person is based on 28,752,719 shares of Common Stock issued and outstanding, as of August 5, 2016, as reported in the Issuer’s Form 10-Q filed with the SEC on August 8, 2016. Pursuant to the regulations promulgated under Section 13(d) of the Act, each of the Reporting Persons constitute members of a group and may be deemed to beneficially own an aggregate of 2,275,455 shares of Common Stock owned by the group, constituting approximately 7.9% of the outstanding shares of Common Stock.
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 10 of 11 |
(c) Except as previously reported or as set forth in this Item 5(c), or otherwise herein, to the knowledge of the Reporting Persons with respect to the persons named in response to Item 5(a), none of the persons named in response to Item 5(a) has effected any transactions in the Common Stock during the past 60 days.
Between August 29, 2016 and September 29, 2016, Aisling sold the following Shares set forth in the table below in open market transactions:
| Date | Shares Sold | Price Per Share |
| August 29, 2016 | 5,000 | $7.5353 |
| August 30, 2016 | 11,200 | $7.3148 |
| August 31, 2016 | 6,900 | $7.2367 |
| September 1, 2016 | 115,198 | $7.4455 |
| September 2, 2016 | 9,703 | $7.2754 |
| September 6, 2016 | 11,777 | $7.0899 |
| September 7, 2016 | 7,426 | $7.0908 |
| September 8, 2016 | 32,796 | $7.0368 |
| September 20, 2016 | 3,138 | $7.4115 |
| September 21, 2016 | 7,777 | $7.4299 |
| September 22, 2016 | 4,220 | $7.3040 |
| September 23, 2016 | 4,364 | $7.2005 |
| September 26, 2016 | 32,843 | $7.2271 |
| September 27, 2016 | 25,253 | $7.3460 |
| September 28, 2016 | 6,023 | $7.3006 |
| September 29, 2016 | 5,000 | $7.1254 |
| September 30, 2016 | 19,724 | $7.0121 |
(d) The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock held for the account of Aisling in accordance with their ownership interests in Aisling.
(e) Not applicable.
| Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. |
No material change.
| Item 7. | Material to be Filed as Exhibits. |
| Exhibit 2: | Fifth Amended and Restated Registration Rights Agreement, dated as of July 18, 2012, by and among the Issuer and the parties listed therein, as modified by the Amendment to Registration Rights Agreement, dated as of May 5, 2014, by and among the Issuer and the parties listed therein (incorporated herein by reference to Exhibit 4.2 to the Form S-1/A filed by the Issuer on May 9, 2014 (File No. 333-194621)). | |
| Exhibit 3: | Joint Filing Agreement dated as of May 30, 2014, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed). | |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 9 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 11 of 11 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: October 3, 2016
| AISLING CAPITAL III, LP | ||||
| By: | Aisling Capital Partners III, LP General Partner | |||
| By: | Aisling Capital Partners III LLC General Partner | |||
| By: | /s/ Dennis Purcell | |||
| Name: Dennis Purcell | ||||
| Title: Managing Member | ||||
| AISLING CAPITAL PARTNERS III, LP | ||||
| By: | Aisling Capital Partners III LLC General Partner | |||
| By: | /s/ Dennis Purcell | |||
| Name: Dennis Purcell | ||||
| Title: Managing Member | ||||
| AISLING CAPITAL PARTNERS III LLC | |||
| By: | /s/ Dennis Purcell | ||
| Name: Dennis Purcell Title: Managing Member | |||
| /s/ Steven Elms | |||
| Steven Elms | |||
| /s/ Dennis Purcell | |||
| Dennis Purcell | |||
| /s/ Andrew Schiff | |||
| Andrew Schiff | |||
Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
